Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE

Wong, Christophe; Stoilova, Ivana; Gazeau, Florence; Herbeuval, Jean-Philippe; Fourniols, Thibaut

doi:10.3389/fimmu.2024.1355845

Cited by 2 publications

(1 citation statement)

References 214 publications

(250 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSC-EVs are nano-sized double-membraned vesicles acting as paracrine effectors of MSCs. The cargo of MSC-EVs contains a diverse range of bioactive molecules, such as proteins, miRNAs, and lipids with great potential in immune modulation, including targeting innate and adaptive immune cells like macrophages, granulocytes, mast cells, NK cells, DCs and lymphocytes [ 154 , 155 ]. MSC-EVs are actively involved in cell–cell communication within the TME.…”

Section: Mscs Contribute To Immunosuppressive Tmementioning

confidence: 99%

Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression

Zhang,

Wang,

2024

Exp Hematol Oncol

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) necessitates a thorough understanding of intricate cellular interactions within the tumor microenvironment (TME). Mesenchymal stromal cells (MSCs) play a pivotal role in cancer generation, progression, and immunosuppressive tumor microenvironment. Within the TME, MSCs encompass both resident and circulating counterparts that dynamically communicate and actively participate in TME immunosurveillance and response to ICB. This review aims to reevaluate various facets of MSCs, including their potential self-transformation to function as cancer-initiating cells and contributions to the creation of a conducive environment for tumor proliferation and metastasis. Additionally, we explore the immune regulatory functions of tumor-associated MSCs (TA-MSCs) and MSC-derived extracellular vesicles (MSC-EVs) with analysis of potential connections between circulating and tissue-resident MSCs. A comprehensive understanding of the dynamics of MSC-immune cell communication and the heterogeneous cargo of tumor-educated versus naïve MSCs may unveil a new MSC-mediated immunosuppressive pathway that can be targeted to enhance cancer control by ICB.

show abstract

Section: Mscs Contribute To Immunosuppressive Tmementioning

confidence: 99%

Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression

Zhang,

Wang,

2024

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

Cell Therapies for Acute Radiation Syndrome

Christy,

Herzig,

et al. 2024

IJMS

View full text Add to dashboard Cite

The risks of severe ionizing radiation exposure are increasing due to the involvement of nuclear powers in combat operations, the increasing use of nuclear power, and the existence of terrorist threats. Exposure to a whole-body radiation dose above about 0.7 Gy results in H-ARS (hematopoietic acute radiation syndrome), which is characterized by damage to the hematopoietic system; higher doses result in further damage to the gastrointestinal and nervous systems. Only a few medical countermeasures for ARS are currently available and approved for use, although others are in development. Cell therapies (cells or products produced by cells) are complex therapeutics that show promise for the treatment of radiation injury and have been shown to reduce mortality and morbidity in animal models. Since clinical trials for ARS cannot be ethically conducted, animal testing is extremely important. Here, we describe cell therapies that have been tested in animal models. Both cells and cell products appear to promote survival and lessen tissue damage after whole-body irradiation, although the mechanisms are not clear. Because radiation exposure often occurs in conjunction with other traumatic injuries, animal models of combined injury involving radiation and future countermeasure testing for these complex medical problems are also discussed.

show abstract

Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE

Cited by 2 publications

References 214 publications

Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression

Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression

Cell Therapies for Acute Radiation Syndrome

Contact Info

Product

Resources

About